
    
      The study will include 210 male or female subjects aged 12 to 35 years diagnosed with T1D, as
      defined by the American Diabetes Association (ADA) criteria and meeting enrollment criteria
      as follows. Initial enrollment will be restricted to subjects aged 18 and older until an
      analysis of data from subjects with 3 months' exposure to drug confirms safety. Upon
      completion of this assessment, enrollment will be open without further restrictions for
      subjects aged 12-35.
    
  